Viatris
VTRS
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Managers holding
3
In their latest 13F (Q3 2026)
See who
Value held
$1.3bn
Combined value at quarter end
Last quarter
2 bought
1 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q2 ’26 end
$15.88
+17.5% in the quarter
Share price change by quarter
+9.2%Q3 ’24
+7.2%Q4 ’24
-30.0%Q1 ’25
+2.5%Q2 ’25
+10.9%Q3 ’25
+25.8%Q4 ’25
+8.5%Q1 ’26
+17.5%Q2 ’26
Managers holding it, by quarter
4Q4 ’23
4Q1 ’24
4Q2 ’24
4Q3 ’24
3Q4 ’24
3Q1 ’25
2Q2 ’25
2Q3 ’25
2Q4 ’25
3Q1 ’26
3Q2 ’26
0Q3 ’26
Who holds it
| Davis Selected Advisers | 5.1%$1.2bn | Trimmed -3.8% |
| Miller Value Partners | 2.8%$11.6m | Added +0.2% |
| Greenlight Capital | 1.1%$44.0m | Added +53% |
About the company
- Sector
- Health care · Pharmaceutical Preparations
- Incorporated in
- Delaware
- Financial year ends
- 31 December
- Shares outstanding
- 1.15bn at 3 Aug 2026
- SEC filings
- Annual reports and other filings on EDGAR
Revenue and profit
$11bn2018
$12bn2019
$12bn2020
$18bn2021
$16bn2022
$15bn2023
$15bn2024
$14bn2025
| Year | Revenue | Net income |
|---|---|---|
| 2025 | $14bn | – |
| 2024 | $15bn | – |
| 2023 | $15bn | – |
| 2022 | $16bn | – |
| 2021 | $18bn | – |
| 2020 | $12bn | – |
| 2019 | $12bn | $0k |
| 2018 | $11bn | – |
In fund portfolios
| Davis Global FundDavis Selected Advisers | 4.5% |